On November 6, 2026 CREATE Medicines, Inc. ("CREATE"), a clinical-stage biotechnology company pioneering in vivo multi-immune programming, reported that members of its senior management team will host one-on-one meetings with investors and prospective partners at the Jefferies Global Healthcare Conference in London, taking place from November 16–19, 2026, at the Waldorf Hilton and ME London. CREATE will be represented by Daniel Getts, PhD, CEO and Co-Founder, and Matthew Maurer, MD, Chief Medical Officer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CREATE is a leader in in vivo CAR therapy, with over 80 patients treated, the largest clinical dataset in the field. The company’s proprietary platform selectively programs immune cells directly inside the body for either transient or stable CAR expression, all from RNA. CREATE’s clinical-stage programs include:

CRT-402, a CD19-targeted in vivo CAR
MT-303, a GPC3-targeted in vivo CAR
MT-302, a TROP2-targeted in vivo CAR
MT-304, a HER2-targeted in vivo CAR
Investors who wish to request a meeting should contact their Jefferies representative. Prospective partners may contact [email protected].

(Press release, Create Medicines, NOV 6, 2026, View Source [SID1234674410])